PRHSX - T. Rowe Price Health Sciences Fund

Nasdaq - Nasdaq Delayed Price. Currency in USD

T. Rowe Price Health Sciences Fund

T. Rowe Price Health Sciences Fund, Inc.

100 East Pratt Street

Baltimore MD 21202

Management Information
Ziad Bakri,Lead Manager since March 31, 2016
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment banking analyst positions in other investment firms
Morningstar Style Box
Yahoo partners with Morningstar a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box which identifies a fund's investment focus, based on the underlying securities in the fund.
Morningstar Category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk, and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. When necessary, we may change a category assignment based on recent changes to the portfolio.

Fund Overview

Fund FamilyT. Rowe Price
Net Assets11.94B
YTD Return8.51%
Morningstar Rating★★★★★
Inception DateDec 28, 1995

Fund Operations

Last Dividend0.00
Last Cap Gain0.00
Holdings Turnover43.00%
Average for CategoryN/A

Fees & Expenses

ExpensePRHSXCategory Average
Annual Report Expense Ratio (net)0.77%1.26%
Prospectus Net Expense Ratio0.77%N/A
Prospectus Gross Expense Ratio0.77%N/A
Max 12b1 FeeN/AN/A
Max Front End Sales LoadN/A5.29%
Max Deferred Sales LoadN/A1.38%
3 Yr Expense Projection246N/A
5 Yr Expense Projection428N/A
10 Yr Expense Projection954N/A